Soligenix Strengthens Medical Advisory Board to Advance HyBryte CTCL Treatment Through Phase 3 Development
Soligenix has updated its U.S. Medical Advisory Board with leading dermatologic and oncologic experts to guide the Phase 3 development and potential commercialization of HyBryte, a novel photodynamic therapy for cutaneous T-cell lymphoma that addresses significant unmet medical needs.
